SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

CSL Limited CSLLY OTC

Other OTC • Healthcare • Biotechnology • AU • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Analyst Price Target

CSL Limited (CSLLY) is a Biotechnology company in the Healthcare sector, currently trading at $24.77. It has a SharesGrow Score of 77/100, indicating a strong investment profile with 6 out of 7 criteria passed.

Analyst consensus target is CSLLY = $307 (+1139.4% upside).

Financials: revenue is $15.4B, +14%/yr average growth. Net income is $3.0B, growing at +1.5%/yr. Net profit margin is 19.5% (healthy). Gross margin is 51.5% (-2.5 pp trend).

Balance sheet: total debt is $11.5B against $19.3B equity (Debt-to-Equity (D/E) ratio 0.59, moderate). Current ratio is 2.46 (strong liquidity). Debt-to-assets is 29.2%. Total assets: $39.4B.

SharesGrow 7-Criteria breakdown: Value 62/100 (Pass), Growth 63/100 (Pass), Past 100/100 (Pass), Health 67/100 (Partial), Moat 75/100 (Pass), Future 100/100 (Pass), Income 70/100 (Pass).

CSLLY SharesGrow Score Overview

77/100

SharesGrow Score

Strong investment profile

View full scorecard →

VALUE 62/100

Valuation — P/E, PEG, Forward PEG

GROWTH 63/100

Financials — average growth

PAST 100/100

strong — trend

HEALTH 67/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 75/100

Gross margin is + market cap

FUTURE 100/100

Analyst outlook — as buy

INCOME 70/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — CSLLY

CSLLY trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $307, implying +1139.4% from the current price $25. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

CSLLY: +14%/yr revenue is, +1.5%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

CSLLY: 4 / 4 years profitable. strong — 100%. Score = 4 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet CSLLY: Debt-to-Equity (D/E) ratio 0.59 (moderate), Current ratio is 2.46 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

CSLLY: Gross margin is 51.5% (-2.5 pp trend), $96B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 75/100. ≥ 70 = Pass.

View details →

Analyst outlook: 0 / 0 analysts rate CSLLY as buy. Analyst consensus target is $307 (+1139.4% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

CSLLY: Net profit margin is 19.5%. healthy (≥15%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range22.83-44.855

Volume26.23K

Avg Volume (30D)425.93K

Market Cap$95.92B

Beta (1Y)0.22

Dividend Yield$0.7300

Share Statistics

EPS (TTM)0.39

Shares Outstanding$3.87B

IPO Date2009-12-29

Employees32,698

CEOGordon Naylor DipCompSc

Financial Highlights & Ratios

Revenue (TTM)$15.43B

Gross Profit$7.95B

EBITDA$5.13B

Net Income$3B

Operating Income$2.96B

Total Cash$2.16B

Total Debt$11.5B

Net Debt$9.34B

Total Assets$39.4B

Price / Earnings (P/E)63.5

Price / Sales (P/S)6.22

Analyst Forecast

1Y Price Target$307.00

Target High$307.00

Target Low$307.00

Upside+1,139.4%

Company Info

CountryAU

ExchangeOther OTC

CurrencyUSD

ISINUS12637N2045

Price Chart

CSLLY

CSL Limited ↗ · Other OTC

Healthcare • Biotechnology

22.83 52WK RANGE 44.86

People Also View

Novo Nordisk A/S

Revolution Medicines, Inc.

Cerevel Therapeutics Holdings, Inc.

Cogent Biosciences, Inc.

Kiniksa Pharmaceuticals, Ltd.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message